Michael F Tweedle, PhD
College of Medicine
Cancer ● Prostatic Cancer ● Breast Cancer ● Leg Ulcer
As a member of the OSUCCC – James Translational Therapeutics Program, Michael Tweedle, MD, focuses on the creation of new molecularly targeted pharmaceuticals visualized in vivo through diagnostic imaging technologies.He is the holder or co-holder of 38 patents. He developed ProHance™, the first nonionic macrocyclic MRI agent, which has been used in more than 50 million patients. He invented the first catalysts for the production of technetium radiopharmaceutical kits for the heart and created some of the earliest targeted molecular-imaging agents from monoclonal antibodies. Most of his projects seek targeted imaging agents that are closely associated biochemically with the therapy so that the patient therapy can be personalized, including co-inventor, first-in-class targeted imaging/therapeutic peptides for prostate and breast cancer, new self-assembled peptide amphiphiles for MRI imaging and a new cell-penetrating peptide for multiple pharmaceutical uses. Dr. Tweedle has co-authored more than 100 peer-reviewed research papers appearing in well-respected publications, including Journal of Nuclear Medicine, Molecular Imaging and Biology and The Journal of Clinical Endocrinology & Metabolism. Additionally, he has shared his research in 13 book chapters in hundreds of presentations at events such as the International Symposium on Macrocyclic and Supramolecular Chemistry, the Symposium on Molecular Imaging Agents, the Contrast Media Research symposium and the American Chemical Society.